Trav14n-3 Inhibitors
Trav14n-1 can engage in various biochemical interactions to impede the protein's function. Staurosporine, a potent kinase inhibitor, can prevent phosphorylation processes essential for Trav14n-1's activity, directly hindering its functional capacity. Similarly, rapamycin, by inhibiting the mTOR pathway, can lead to a reduction in the translational efficiency of Trav14n-1 or increase its degradation through autophagy, effectively reducing its cellular activity. Bortezomib disrupts the proteasomal degradation machinery, potentially leading to an indirect inhibition of Trav14n-1 by affecting its degradation. Trichostatin A, a histone deacetylase inhibitor, may induce the expression of proteins that negatively regulate Trav14n-1, thereby impacting its stability or function.
LY294002 and Wortmannin, both PI3K inhibitors, can suppress the kinase activity that could be upstream of Trav14n-1, leading to reduced phosphorylation of proteins within its signaling pathway and subsequent inhibition. U0126 targets the MEK enzyme in the MAPK/ERK pathway, and its inhibition may lead to diminished activation of proteins necessary for Trav14n-1's function. In a parallel manner, SP600125 and SB203580, which inhibit JNK and p38 MAPK respectively, can disrupt the kinase signaling cascades that Trav14n-1 may rely on for its regulatory functions. Dasatinib, as a Src family kinase inhibitor, has the potential to reduce phosphorylation events by Src family kinases on Trav14n-1, thereby inhibiting its activity. Imatinib, by inhibiting specific tyrosine kinases, can prevent critical phosphorylation that Trav14n-1 requires for activation. Lastly, Sorafenib's inhibition of RAF kinase may lead to decreased Trav14n-1 activity if it is part of the RAF/MEK/ERK signaling pathway, demonstrating the broad spectrum of chemical interactions that can inhibit the function of Trav14n-1.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent non-selective inhibitor of protein kinases, which may inhibit Trav14n-1 by preventing phosphorylation events that are necessary for its activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, a kinase that can regulate protein translation and autophagy, potentially reducing the functional availability of Trav14n-1 by limiting its translation efficiency or increasing its degradation. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor, which could lead to an accumulation of ubiquitinated proteins and possibly interfere with the degradation pathway of Trav14n-1, assuming Trav14n-1 is regulated by proteasomal degradation. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor that can alter gene expression profiles, which might lead to upregulation of proteins that negatively regulate Trav14n-1 activity or stability. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor, potentially reducing the phosphorylation of downstream targets that might be involved in the signaling cascade of Trav14n-1, thus inhibiting its function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor, similar to LY294002, and could inhibit Trav14n-1 function by reducing the phosphorylation of proteins within its signaling pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK, which is part of the MAPK/ERK pathway; inhibition of this pathway could lead to decreased activation of downstream proteins that may be necessary for Trav14n-1 activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, and by inhibiting JNK activity, it could decrease the regulatory influence of JNK on Trav14n-1 function, assuming there's a link between JNK signaling and Trav14n-1. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor, which could inhibit Trav14n-1 function by disrupting the p38 MAPK pathway that might be implicated in the regulation or activity of Trav14n-1. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a Src family kinase inhibitor, which may inhibit Trav14n-1 by reducing the activity of Src family kinases that could phosphorylate and activate Trav14n-1. | ||||||